Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 30 12 2020
accepted: 09 04 2021
entrez: 21 6 2021
pubmed: 22 6 2021
medline: 7 10 2021
Statut: epublish

Résumé

T cell dysfunction occurs early following HIV infection, impacting the emergence of non-AIDS morbidities and limiting curative efforts. ART initiated during primary HIV infection (PHI) can reverse this dysfunction, but the extent of recovery is unknown. We studied 66 HIV-infected individuals treated from early PHI with up to three years of ART. Compared with HIV-uninfected controls, CD4 and CD8 T cells from early HIV infection were characterised by T cell activation and increased expression of the immune checkpoint receptors (ICRs) PD1, Tim-3 and TIGIT. Three years of ART lead to partial - but not complete - normalisation of ICR expression, the dynamics of which varied for individual ICRs. For HIV-specific cells, epigenetic profiling of tetramer-sorted CD8 T cells revealed that epigenetic features of exhaustion typically seen in chronic HIV infection were already present early in PHI, and that ART initiation during PHI resulted in only a partial shift of the epigenome to one with more favourable memory characteristics. These findings suggest that although ART initiation during PHI results in significant immune reconstitution, there may be only partial resolution of HIV-related phenotypic and epigenetic changes.

Identifiants

pubmed: 34149690
doi: 10.3389/fimmu.2021.647688
pmc: PMC8213372
doi:

Substances chimiques

Anti-Retroviral Agents 0
Antibodies, Viral 0
HAVCR2 protein, human 0
Hepatitis A Virus Cellular Receptor 2 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Receptors, Immunologic 0
TIGIT protein, human 0

Types de publication

Journal Article Multicenter Study Observational Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

647688

Subventions

Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011233/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N001265/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L00528X/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Martin, Sen, Pace, Robinson, Meyerowitz, Adland, Thornhill, Jones, Ogbe, Parolini, Olejniczak, Zacharopoulou, Brown, Willberg, Nwokolo, Fox, Fidler, Haining and Frater.

Déclaration de conflit d'intérêts

WH is an employee of Merck and Company and holds equity in Tango Therapeutics and Arsenal Biosciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
J Infect Dis. 2013 Oct 15;208(8):1202-11
pubmed: 23852127
J Immunol. 2013 Jul 15;191(2):540-4
pubmed: 23772031
Front Immunol. 2014 May 14;5:217
pubmed: 24860576
Nat Methods. 2013 Dec;10(12):1213-8
pubmed: 24097267
J Exp Med. 2008 Nov 24;205(12):2763-79
pubmed: 19001139
Sci Rep. 2017 Jan 13;7:40354
pubmed: 28084312
JAMA Intern Med. 2015 Jan;175(1):88-99
pubmed: 25419650
Nature. 2018 Feb 8;554(7691):239-243
pubmed: 29420474
Nat Commun. 2017 Sep 8;8(1):498
pubmed: 28887441
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
J Med Virol. 2010 Mar;82(3):358-70
pubmed: 20087935
PLoS Pathog. 2016 Aug 03;12(8):e1005805
pubmed: 27486665
PLoS Pathog. 2012;8(8):e1002840
pubmed: 22916009
J Infect Dis. 2000 Jan;181(1):121-31
pubmed: 10608758
JCI Insight. 2021 Feb 8;6(3):
pubmed: 33400687
Antivir Ther. 2011;16(4):535-45
pubmed: 21685541
Immunity. 2016 Aug 16;45(2):358-73
pubmed: 27496729
J Infect Dis. 2011 May 15;203(10):1491-502
pubmed: 21502085
J Infect Dis. 2020 Mar 16;221(7):1135-1145
pubmed: 31776569
Nat Med. 2020 Apr;26(4):519-528
pubmed: 32284611
J Exp Med. 2006 Oct 2;203(10):2281-92
pubmed: 16954372
Cell. 2013 Nov 7;155(4):934-47
pubmed: 24119843
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
J Virol. 2009 Feb;83(3):1228-39
pubmed: 19019964
N Engl J Med. 2013 Jan 17;368(3):207-17
pubmed: 23323897
AIDS Res Hum Retroviruses. 2017 Jul;33(7):658-667
pubmed: 28335609
PLoS Med. 2008 May 6;5(5):e100
pubmed: 18462013
Curr HIV/AIDS Rep. 2014 Mar;11(1):20-34
pubmed: 24414166
J Immunol. 2013 Sep 1;191(5):2194-204
pubmed: 23918986
AIDS. 2007 Oct 1;21(15):2005-13
pubmed: 17885290
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
Curr Protoc Mol Biol. 2015 Jan 05;109:21.29.1-21.29.9
pubmed: 25559105
PLoS Pathog. 2016 Jul 14;12(7):e1005761
pubmed: 27415008
Nature. 2006 Sep 21;443(7109):350-4
pubmed: 16921384
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
PLoS One. 2008 Feb 27;3(2):e1678
pubmed: 18301755
Sci Transl Med. 2019 May 22;11(493):
pubmed: 31118290
Cell. 2013 Apr 11;153(2):307-19
pubmed: 23582322
J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):505-8
pubmed: 23314410
J Infect Dis. 2005 May 1;191(9):1410-8
pubmed: 15809898
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202771
Blood. 2007 Jun 1;109(11):4671-8
pubmed: 17272504
Blood. 2011 May 5;117(18):4805-15
pubmed: 21398582
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
Science. 2014 Jul 11;345(6193):179-83
pubmed: 24968937
Science. 2018 Oct 26;362(6413):
pubmed: 30361341
Clin Infect Dis. 2017 Jan 15;64(2):124-131
pubmed: 27737952
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
J Infect Dis. 2019 Nov 6;220(12):1885-1891
pubmed: 30668739
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
J Exp Med. 2004 Sep 20;200(6):701-12
pubmed: 15381726
J Immunol. 2019 Oct 15;203(8):2210-2221
pubmed: 31519862
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19480
pubmed: 25393989
J Virol. 2006 Jul;80(14):7226-34
pubmed: 16809328
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
PLoS Pathog. 2016 Jan 07;12(1):e1005349
pubmed: 26741490
J Exp Med. 2000 Jul 3;192(1):63-75
pubmed: 10880527
Science. 2012 Nov 30;338(6111):1220-5
pubmed: 23197535
Science. 2016 Dec 2;354(6316):1165-1169
pubmed: 27789799
Sci Rep. 2015 Jun 03;5:10879
pubmed: 26039976
Lancet HIV. 2018 Jun;5(6):e317-e328
pubmed: 29893245
AIDS. 2014 Jul 31;28(12):1749-58
pubmed: 24871455
PLoS Pathog. 2016 Jul 14;12(7):e1005661
pubmed: 27415828
Nat Commun. 2015 Oct 09;6:8495
pubmed: 26449164
Nat Immunol. 2011 May 29;12(7):663-71
pubmed: 21623380
PLoS Pathog. 2014 Jul 17;10(7):e1004251
pubmed: 25032686
Science. 2016 Dec 2;354(6316):1160-1165
pubmed: 27789795
Clin Infect Dis. 2016 Jan 15;62(2):250-257
pubmed: 26349551
Clin Infect Dis. 2018 May 2;66(10):1519-1527
pubmed: 29211834
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7
pubmed: 10737796

Auteurs

Genevieve E Martin (GE)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Department of Infectious Diseases, Monash University, Melbourne, VIC, Australia.

Debattama R Sen (DR)

Department of Immunology, Harvard Medical School, Boston, MA, United States.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.

Matthew Pace (M)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Nicola Robinson (N)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Jodi Meyerowitz (J)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Emily Adland (E)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

John P Thornhill (JP)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Division of Medicine, Wright Fleming Institute, Imperial College, London, United Kingdom.

Mathew Jones (M)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Ane Ogbe (A)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Lucia Parolini (L)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Natalia Olejniczak (N)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Panagiota Zacharopoulou (P)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Helen Brown (H)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Christian B Willberg (CB)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Oxford National Institute of Health Research Biomedical Research Centre, Oxford, United Kingdom.

Nneka Nwokolo (N)

Chelsea and Westminster Hospital, London, United Kingdom.

Julie Fox (J)

Department of Genitourinary Medicine and Infectious Disease, Guys and St Thomas' National Health Service (NHS) Trust, London, United Kingdom.
King's College National Institute of Health Research (NIHR) Biomedical Research Centre, London, United Kingdom.

Sarah Fidler (S)

Division of Medicine, Wright Fleming Institute, Imperial College, London, United Kingdom.
Imperial College NIHR Biomedical Research Centre, London, United Kingdom.

W Nicholas Haining (WN)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Discovery Oncology and Immunology, Merck Research Laboratories, Boston, MA, United States.

John Frater (J)

Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Oxford National Institute of Health Research Biomedical Research Centre, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH